CR20240296A - Inhibidores parp1 - Google Patents
Inhibidores parp1Info
- Publication number
- CR20240296A CR20240296A CR20240296A CR20240296A CR20240296A CR 20240296 A CR20240296 A CR 20240296A CR 20240296 A CR20240296 A CR 20240296A CR 20240296 A CR20240296 A CR 20240296A CR 20240296 A CR20240296 A CR 20240296A
- Authority
- CR
- Costa Rica
- Prior art keywords
- parp1
- parp1 inhibitors
- treating
- inhibitors
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292903P | 2021-12-22 | 2021-12-22 | |
| US202263327228P | 2022-04-04 | 2022-04-04 | |
| US202263403459P | 2022-09-02 | 2022-09-02 | |
| PCT/US2022/053591 WO2023122140A1 (en) | 2021-12-22 | 2022-12-21 | Parp1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20240296A true CR20240296A (es) | 2024-09-18 |
Family
ID=85156997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20240296A CR20240296A (es) | 2021-12-22 | 2022-12-21 | Inhibidores parp1 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250163022A1 (https=) |
| EP (1) | EP4452963A1 (https=) |
| JP (1) | JP2025501762A (https=) |
| KR (1) | KR20240136978A (https=) |
| AU (1) | AU2022420969A1 (https=) |
| CA (1) | CA3241875A1 (https=) |
| CL (1) | CL2024001874A1 (https=) |
| CO (1) | CO2024009571A2 (https=) |
| CR (1) | CR20240296A (https=) |
| IL (1) | IL313727A (https=) |
| MX (1) | MX2024007673A (https=) |
| PE (1) | PE20242004A1 (https=) |
| TW (1) | TW202332438A (https=) |
| WO (1) | WO2023122140A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240208923A1 (en) | 2021-03-10 | 2024-06-27 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| IL315586A (en) * | 2022-03-11 | 2024-11-01 | Impact Therapeutics Shanghai Inc | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| EP4545531A1 (en) * | 2022-06-27 | 2025-04-30 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Tricyclic compounds and uses thereof |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| JP2025535834A (ja) * | 2022-11-02 | 2025-10-28 | スアンズ バイオファーマシューティカル カンパニー，リミテッド | 多環式ポリ（ａｄｐリボース）ポリメラーゼ選択的阻害剤 |
| JP2025538192A (ja) * | 2022-11-10 | 2025-11-26 | 上海海和薬物研究開発股▲ふん▼有限公司 | 縮合三環式ｐａｒｐ１阻害剤、その調製方法、および使用 |
| WO2024227026A1 (en) * | 2023-04-28 | 2024-10-31 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as parp1 inhibitors |
| CN119462669A (zh) * | 2023-08-11 | 2025-02-18 | 上海海和药物研究开发股份有限公司 | 稠合三环类化合物、其药物组合物和用途 |
| WO2025067417A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都赜灵生物医药科技有限公司 | 并内酰胺环类化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2459561A1 (en) * | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| CA2937012A1 (en) * | 2013-10-23 | 2015-04-30 | Sumitomo Dainippon Pharma Co., Ltd. | Fused pyrazole derivative |
| PH12017502228B1 (en) * | 2015-06-09 | 2022-08-03 | Onconic Therapeutics Inc | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| MX2022000711A (es) * | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
-
2022
- 2022-12-21 JP JP2024538278A patent/JP2025501762A/ja active Pending
- 2022-12-21 WO PCT/US2022/053591 patent/WO2023122140A1/en not_active Ceased
- 2022-12-21 EP EP22851230.7A patent/EP4452963A1/en active Pending
- 2022-12-21 PE PE2024001409A patent/PE20242004A1/es unknown
- 2022-12-21 AU AU2022420969A patent/AU2022420969A1/en active Pending
- 2022-12-21 IL IL313727A patent/IL313727A/en unknown
- 2022-12-21 CA CA3241875A patent/CA3241875A1/en active Pending
- 2022-12-21 KR KR1020247024155A patent/KR20240136978A/ko active Pending
- 2022-12-21 CR CR20240296A patent/CR20240296A/es unknown
- 2022-12-21 TW TW111149299A patent/TW202332438A/zh unknown
- 2022-12-21 MX MX2024007673A patent/MX2024007673A/es unknown
- 2022-12-21 US US18/728,407 patent/US20250163022A1/en active Pending
-
2024
- 2024-06-19 CL CL2024001874A patent/CL2024001874A1/es unknown
- 2024-07-19 CO CONC2024/0009571A patent/CO2024009571A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL313727A (en) | 2024-08-01 |
| JP2025501762A (ja) | 2025-01-23 |
| TW202332438A (zh) | 2023-08-16 |
| EP4452963A1 (en) | 2024-10-30 |
| WO2023122140A1 (en) | 2023-06-29 |
| CL2024001874A1 (es) | 2024-12-06 |
| AU2022420969A1 (en) | 2024-06-13 |
| MX2024007673A (es) | 2024-09-06 |
| CO2024009571A2 (es) | 2024-07-29 |
| PE20242004A1 (es) | 2024-10-03 |
| US20250163022A1 (en) | 2025-05-22 |
| CA3241875A1 (en) | 2023-06-29 |
| KR20240136978A (ko) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20240296A (es) | Inhibidores parp1 | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| ZA201807399B (en) | Egfr inhibitor compounds | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| PH12021551463A1 (en) | Modulators of hsd17b13 expression | |
| PH12019500957A1 (en) | Selective inhibitor of exon 20 insertion mutant egfr | |
| PH12020551995A1 (en) | Modulator of apol1 expression | |
| ZA202105742B (en) | Modulators of malat1 expression | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MY194227A (en) | Modulators of pcsk9 expression | |
| ZA202004848B (en) | Modulators of irf4 expression | |
| WO2020055643A3 (en) | Compounds, compositions and methods for treating or preventing her-driven cancers | |
| WO2020205646A3 (en) | Small molecule parg inhibitors and methods of use thereof | |
| MX2020007369A (es) | Moduladores de la expresion de dnm2. | |
| MX2022007628A (es) | Combinaciones. | |
| MX2022007626A (es) | Combinaciones. | |
| MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
| MX2024012789A (es) | Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa) | |
| JOP20210108A1 (ar) | معدِّلات تعبير irf5 | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| WO2019032810A3 (en) | Methods and materials for identifying and treating bet inhibitor-resistant cancers | |
| MX2022007625A (es) | Combinaciones. | |
| MX2022007624A (es) | Combinaciones. | |
| AR129088A1 (es) | INHIBIDORES DE PI3Ka |